Superluminal Medicines

Superluminal Medicines is a drug discovery company that combines structure-based drug discovery with AI-powered computational methods and experimental validation to identify and develop small molecule therapeutics. Its pipeline targets G protein-coupled receptors (GPCRs) for cardiometabolic disease and obesity, including a collaboration with Eli Lilly worth up to $1.3 billion. Backed by Insight Partners. No public developer API, SDK, or documentation surface was found as of this enrichment pass.

Superluminal Medicines is profiled on the APIs.io network. Tagged areas include Company, Biotech Therapeutics, Drug Discovery, Artificial Intelligence, and Small Molecule Therapeutics.

🌐 Visit website 📡 Source on GitHub
7.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyBiotech TherapeuticsDrug DiscoveryArtificial IntelligenceSmall Molecule TherapeuticsGPCRLife Sciences

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 7.7/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.0 / 20
Commercial Clarity 0.0 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/superluminal-medicines: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Superluminal Medicines Domain Security

TLSv1.3 · HSTS · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Company 1

The organization behind the API

Website
Website

Source (apis.yml)

apis.yml Raw ↑ 
aid: superluminal-medicines
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/superluminal-medicines.png
name: Superluminal Medicines
description: Superluminal Medicines is a drug discovery company that combines structure-based drug discovery with AI-powered
  computational methods and experimental validation to identify and develop small molecule therapeutics. Its pipeline targets
  G protein-coupled receptors (GPCRs) for cardiometabolic disease and obesity, including a collaboration with Eli Lilly worth
  up to $1.3 billion. Backed by Insight Partners. No public developer API, SDK, or documentation surface was found as of this
  enrichment pass.
url: https://raw.githubusercontent.com/api-evangelist/superluminal-medicines/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- insight-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-21'
tags:
- Company
- Biotech Therapeutics
- Drug Discovery
- Artificial Intelligence
- Small Molecule Therapeutics
- GPCR
- Life Sciences
common:
- type: DomainSecurity
  url: security/superluminal-medicines-domain-security.yml
- type: Website
  url: https://www.superluminalrx.com
apis: []
x-enrichment:
  date: '2026-07-21'
  status: minimal
  artifacts_added: 1
  pass: local-v1
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io